507 related articles for article (PubMed ID: 26981243)
21. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.
Koelzer VH; Buser T; Willi N; Rothschild SI; Wicki A; Schiller P; Cathomas G; Zippelius A; Mertz KD
J Immunother Cancer; 2016; 4():47. PubMed ID: 27532022
[TBL] [Abstract][Full Text] [Related]
22. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
23. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.
Reuss JE; Kunk PR; Stowman AM; Gru AA; Slingluff CL; Gaughan EM
J Immunother Cancer; 2016; 4():94. PubMed ID: 28031822
[TBL] [Abstract][Full Text] [Related]
24. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade.
Tsai KK; Pampaloni MH; Hope C; Algazi AP; Ljung BM; Pincus L; Daud AI
J Immunother Cancer; 2016; 4():58. PubMed ID: 27660712
[TBL] [Abstract][Full Text] [Related]
25. Unusual pulmonary toxicity of ipilimumab treated by macrolides.
Mailleux M; Cornélis F; Colin GC; Baurain JF
Acta Clin Belg; 2015 Dec; 70(6):442-4. PubMed ID: 26790556
[TBL] [Abstract][Full Text] [Related]
26. Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors.
Rose LM; DeBerg HA; Vishnu P; Frankel JK; Manjunath AB; Flores JPE; Aboulafia DM
Front Oncol; 2020; 10():570752. PubMed ID: 33520695
[TBL] [Abstract][Full Text] [Related]
27. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
28. Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.
Sidhu P; Menzies AM; Long G; Carlino M; Lorens S; Kapoor R
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):759-766. PubMed ID: 29024572
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
30. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Heinzerling L; Ott PA; Hodi FS; Husain AN; Tajmir-Riahi A; Tawbi H; Pauschinger M; Gajewski TF; Lipson EJ; Luke JJ
J Immunother Cancer; 2016; 4():50. PubMed ID: 27532025
[TBL] [Abstract][Full Text] [Related]
31. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism.
Win MA; Thein KZ; Qdaisat A; Yeung SJ
Am J Emerg Med; 2017 Jul; 35(7):1039.e5-1039.e7. PubMed ID: 28363614
[TBL] [Abstract][Full Text] [Related]
32. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.
Anderson D; Beecher G; Nathoo N; Smylie M; McCombe JA; Walker J; Jassal R
Neurooncol Pract; 2019 Sep; 6(5):340-345. PubMed ID: 31555448
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.
Simeone E; Grimaldi AM; Festino L; Trojaniello C; Vitale MG; Vanella V; Palla M; Ascierto PA
Melanoma Manag; 2019 Nov; 6(4):MMT30. PubMed ID: 31871619
[TBL] [Abstract][Full Text] [Related]
34. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.
Papavasileiou E; Prasad S; Freitag SK; Sobrin L; Lobo AM
Ocul Immunol Inflamm; 2016; 24(2):140-6. PubMed ID: 25760920
[TBL] [Abstract][Full Text] [Related]
35. Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.
Werner JM; Schweinsberg V; Schroeter M; von Reutern B; Malter MP; Schlaak M; Fink GR; Mauch C; Galldiks N
Front Oncol; 2019; 9():84. PubMed ID: 30828569
[TBL] [Abstract][Full Text] [Related]
36. Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma.
Angell TE; Min L; Wieczorek TJ; Hodi FS
Genes Dis; 2018 Mar; 5(1):46-48. PubMed ID: 29619406
[TBL] [Abstract][Full Text] [Related]
37. Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.
Gowen MF; Giles KM; Simpson D; Tchack J; Zhou H; Moran U; Dawood Z; Pavlick AC; Hu S; Wilson MA; Zhong H; Krogsgaard M; Kirchhoff T; Osman I
J Transl Med; 2018 Apr; 16(1):82. PubMed ID: 29606147
[TBL] [Abstract][Full Text] [Related]
38. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors.
Youssef A; Kasso N; Torloni AS; Stanek M; Dragovich T; Gimbel M; Mahmoud F
Case Rep Hematol; 2018; 2018():2464619. PubMed ID: 30671268
[TBL] [Abstract][Full Text] [Related]
39. Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report.
Matull J; Livingstone E; Wetter A; Zimmer L; Zaremba A; Lahner H; Schadendorf D; Ugurel S
Front Oncol; 2020; 10():592609. PubMed ID: 33262949
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
Eggermont AM; Maio M; Robert C
Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
